期刊文献+

E2F3在浸润性膀胱癌中的表达关系以及对患者生存的影响 被引量:6

The clinical significance of E2F3 and RB expressions, and their effect on prognosis in bladder cancer
原文传递
导出
摘要 目的 探讨转录因子家族(E2F)3以及Retinoblastoma(RB)在膀胱癌组织中的表达情况,并明确RB通路失活与E2F3高表达在膀胱癌组织中的关系及对膀胱癌患者预后的影响.方法 通过免疫组织化学法验证E2F3和RB在112例膀胱癌组织中的表达,分析其表达水平与患者的临床分期、病理分级之间的关系.结果 在112例不同分期的膀胱癌组织样本中,有83例膀胱癌样本表现为RB的失活,这种表达差异具有统计学意义(P<0.01),E2F3高表达只出现在浸润性膀胱癌中(x2 =8.67,P<0.01),并且与RB失活关系密切(r=0.031,P=0.014).生存曲线显示,E2F3过表达对膀胱癌患者预后有着一定的影响(P<0.05).结论 E2F3在浸润性膀胱癌中高表达,并且与RB失活存在着密切的关系,同时E2F3高表达的膀胱肿瘤患者预后更差. Objective To investigate the expressions of transcription factor (E2F) 3 and retinoblastoma (RB),and define the specific relationship between RB inactivation and E2F3 overexpression in individual bladder tumors.Methods The expression of E2F3 was investigate with immunohistochemistry in 112 bladder samples.The relationships between the expression of E2F3 and clinical grade,stage,and prognosis were analyzed.Results In 112 cases of tissue samples,83 cases of bladder cancer samples showed RB inactivation,this expression difference was statistically significant (P 〈0.01);E2F3 appeared only in invasive bladder cancer (x2 =8.67,P 〈 0.01) with a close relationship with RB (r =0.031,P =0.014).Survival curves were observed,overexpressed E2F3 has a worse prognosis (P 〈 0.05).Concluo sions E2F3 was overexpressed in bladder cancer and was closely associated with RB inactivation.
出处 《中国医师杂志》 CAS 2016年第1期29-32,共4页 Journal of Chinese Physician
基金 国家自然科学基金(31272391)
关键词 E2F3转录因子/代谢 膀胱肿瘤/代谢 预后 E2F3 transcription factor/ME Urinary bladder neoplasms/ME Prognosis
  • 相关文献

参考文献9

  • 1Burkhart DL, SageJ. Cellular mechanisms of tumour suppression by the retinoblastoma gene[J]. Nat Rev Cancer, 2008, 8 (9) : 671-682. DOl: 1O.1038/nrc2399.
  • 2Chen HZ, Tsai SY, Leone G.? Emerging roles of E2Fs in cancer: An exit from cell cycle control[J]. Nat Rev Cancer, 2009, 9 (11 ) : 785-797. DOl: 1O.1038/nrc2696.
  • 3Huang L, LuoJ, Cai Q, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3[J]. IntJ Cancer, 2011 ,128(8) :1758-1769. DOl: 1O.1002/ijc. 25509.
  • 4Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: update 2013[J]. Eur Urol, 2013 ,64( 4) :639-653. DOl: 10. 1016/j. eururo. 2013. 06. 003.
  • 5李瑞晓,于垂恭,张璟,袁建林,武国军.抑癌候选基因NDRG2在膀胱肿瘤中的表达研究[J].中国医师杂志,2012,14(12):1585-1588. 被引量:2
  • 6Lemmens T, Telfer C. Access to information and the right to health: the human rights case for clinical trials transparency[J]. AmJ Law Med,2012,38(l) :63-112.
  • 7Rotgers E, Rivero-Muller A, Nurmio M, et al. Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of Sertoli cells[J]. Cell Death Dis, 2014,5: el274. DOl: 10. 1038/cddis. 2014. 232.
  • 8Aslanian A, Iaquinta PJ, Verona R, et al. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics[J]. Genes Dev, 2004, 18 ( 12) : 14l3-1422. DOl: 10. 1101/ gad. 1196704.
  • 9Leone G, Nuckolls F, Ishida S, et al. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins[J]. Mol Cell Bioi, 2000, 20 ( 10 ) : 3626-3632. DOl: 10. 1128/MCB. 20. 10.3626-3632.2000.

二级参考文献4

共引文献1

同被引文献28

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部